Navigation Links
Vanderbilt study looks at benefits of progestogens to prevent early childbirth
Date:9/10/2012

Pregnant women who have had prior preterm births may avoid a subsequent early birth if given progestogens, which are natural or synthetic forms of progesterone, a female hormone that naturally increases during pregnancy, a Vanderbilt analysis shows.

Women who have had prior preterm births and are given progestogens while expecting a single child show some benefit from additional hormone, Vanderbilt researchers reported in a systematic review released on Thursday in Obstetrics & Gynecology, the official publication of the American College of Obstetricians and Gynecologists, commonly referred to as The Green Journal.

The researchers looked at 34 prior studies of women who were given progestogens for prior preterm births, multiple gestations, preterm labor, short cervix or other indications. Each study included 20 or more women who were given the medication by injection, orally or vaginally, and took place between January 1966 and October 2011.

The work was funded by the Agency for Healthcare Research and Quality (AHRQ).

In contrast, the researchers found progestogens don't seem to help prevent preterm labor in women carrying twins or triplets. And evidence supporting giving progestogens for all other uses is insufficient to guide clinical care.

The review provides valuable information, but more study is needed, said Frances E. Likis, DrPH, N.P., CNM, research assistant professor of Medicine and the lead author of the review. "While we know that women have progesterone levels that go up in early pregnancy and remain elevated, we still don't understand why giving extra progestogens would help them stay pregnant," she said. "The pharmaceutical effects are not well understood."

The United States has a very high preterm birth rate and was among the top 10 countries with the highest numbers of preterm births in 2010. "We haven't been able to move that number very well, and although it's gone down somewhat in past years, it's not a dramatic drop," she said.

Along with the systematic review, the AHRQ is releasing Vanderbilt's longer report on progestogens for preterm birth prevention online today. The full report looks at other questions such as whether how progestogens are administered makes a difference in effectiveness and the adverse effects of progestogens for preterm birth.

Progestogens are usually given by clinicians to women at the beginning of the second trimester through 37 weeks gestation or until the baby is born. Most women receive the medication once a week by injection, although some receive it vaginally. Very few take an oral dose.

Likis said asking generally whether progestogens are beneficial isn't possible. "Women are being given progestogens for very different reasons, so in our review, we decided to look at effectiveness by why women took it. Having had a previous preterm birth is different from having twins, and that's how clinicians make decisions. They don't just look at women and say 'you're at risk,' they say 'what is your risk factor?'"

To look at complications, a larger group of women is needed, she said. "There's relatively little evidence about whether babies had complications, and there's also very little information about long-term health effects in the infant," she said. "There's a lot more that needs to be studied. There's a lot of work to be done."
'/>"/>

Contact: Craig Boerner
craig.boerner@vanderbilt.edu
615-322-4747
Vanderbilt University Medical Center
Source:Eurekalert

Related medicine news :

1. Vanderbilt-led study reveals racial disparities in prostate cancer care
2. Vanderbilt researchers find proteins may point way to new prostate cancer drug targets
3. Vanderbilt study finds obesity linked to kidney injury after heart surgery
4. Young Children Treated for Cancer May Be at Risk for PTSD: Study
5. Physicians empathy directly associated with positive clinical outcomes, confirms large study
6. Study identifies genes associated with genomic expansions that cause disease
7. Multiple Methods Can Safely Help Babies Get to Sleep, Study Shows
8. Large lung cancer study shows potential for more targeted therapies
9. Chemo Brain After Breast Cancer Backed by Study
10. X-Rays May Up Breast Cancer Risk for Women With Certain Genes: Study
11. Cedars-Sinai Heart Institute awarded $1.3 million to study cardiac stem cells
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/5/2016)... ... May 05, 2016 , ... Einstein Medical is ... to cover the latest news and commentary at the 2016 ASCRS/ASOA Symposium and Congress, ... the American Society of Cataract and Refractive Surgery and the American Society of Ophthalmic ...
(Date:5/5/2016)... ... May 05, 2016 , ... Spring Fertility , the ... and with egg freezing, today announced the grand opening of its first location ... care, Spring Fertility offers both fertility preservation (egg, sperm, embryo, and testicular and ...
(Date:5/5/2016)... ... May 05, 2016 , ... United Benefit Advisors (UBA), ... as the latest addition to its family of Partner Firms. Headquartered in Mount ... wellness, human resources, and health care consumerism specialists. , “Partnering with UBA will ...
(Date:5/5/2016)... (PRWEB) , ... May 05, 2016 , ... ... commencement of a master charity program created to assist the people of their ... working closely with nonprofit organizations and community leaders. Their hope is to bring ...
(Date:5/5/2016)... ... 05, 2016 , ... Tim Dieter has announced the latest ... Dubuque, IA. The current campaign fundraises for Veteran’s Freedom Center on behalf of ... Freedom Center may now be made here: http://www.veteransfreedomcenter.com/donate/ . , Veteran’s Freedom ...
Breaking Medicine News(10 mins):
(Date:5/3/2016)... -- Research and Markets has announced the ... Market Outlook 2020" report to their offering. ... technology has improved significantly in past years due to ... coming years. Many cancer drugs have been developed by ... also expected to be developed with its help. They ...
(Date:5/3/2016)... 3, 2016   BIOTRONIK , a leader ... Food and Drug Administration (FDA) approval of Iperia ... heart failure patients with access to diagnostic magnetic ... remote monitoring with daily automatic transmission and closed ... in response to physiological demands. ...
(Date:5/3/2016)... -- Pharmaceutical giant Johnson & Johnson has ... who says its talc-based powder products caused ovarian cancer. ... $5 million in compensatory damages and $50 million in ... ) , This is the second in ... the same court awarded $72 million to the family ...
Breaking Medicine Technology: